T-Cypher Bio develops T-cell receptor-based therapeutics that utilize proprietary target screening libraries to identify functionally defined T-cell clones from disease tissues, specifically for solid tumors and other immune-mediated diseases. This approach enables healthcare providers to create tailored cell therapies that address the limitations of existing cancer treatments by targeting a broader range of tumor-specific antigens.
Funding
$24.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
OSFounders
Product
Problem
Current cancer treatments often fail to address the full spectrum of tumor-specific antigens, leading to limited efficacy and potential for relapse in patients with solid tumors and immune-mediated diseases. Existing cell therapies may not be tailored to the unique T-cell clones present in individual disease tissues.
Solution
T-Cypher Bio develops T-cell receptor (TCR)-based therapeutics by identifying functionally-defined T-cell clones directly from patient disease tissues using proprietary target screening libraries. This approach enables the creation of personalized cell therapies that target a broader range of tumor-specific antigens, addressing the limitations of existing cancer treatments. The company's high-throughput, high-resolution profiling of the immune synapse allows for mapping of the intracellular target space and profiling of T-cell specificity. T-Cypher Bio's platforms generate large immune system datasets that support computational modeling of T-cell repertoires, providing insights into T-cell immunology and facilitating the development of innovative drugs.
Target Audience
The primary target audience includes healthcare providers specializing in oncology and immunology, as well as patients with solid tumors and immune-mediated diseases who could benefit from tailored cell therapies.
Features
- Proprietary target screening libraries for identifying functionally-defined T-cell clones.
- High-throughput, high-resolution profiling of the immune synapse.
- Identification of novel, shared, tumor-specific targets.
- Validation of rare, functionally-defined T-cell clones.
- Computational modeling of T-cell repertoires for enhanced target discovery.
- TCR-based therapeutics for solid tumors and immune-mediated diseases.